Crisaborole

DAE Class; Rx

Common Brand Names; Eucrisa

• PDE-4 Inhibitors, Topical

Topical phosphodiesterase 4 inhibitor
For treatment of mild to moderate atopic dermatitis in patients 3 months and older
Most common adverse reaction is application site pain

Indicated for mild-to-moderate atopic dermatitis

History of hypersensitivity to crisaborole or any component of the formulation

1-10%

Application site pain, burning, or stinging (4%)

<1%

Contact urticaria

Postmarketing Reports

Allergic contact dermatitis

Hypersensitivity reactions reported, including contact urticaria; signs and symptoms may include severe pruritus, swelling, and erythema at the application site or at a distant site; discontinue immediately and initiate appropriate therapy if hypersensitivity suspected (see Contraindications)

Pregnancy

Available data from case reports with use in pregnant women are insufficient to inform a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes

Crisaborole is systemically absorbed

Lactation

Unknown if distributed in human breast milk

Crisaborole is systemically absorbed

Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition

Adults

Specific maximum dosage information not available.

Geriatric

Specific maximum dosage information not available.

Adolescents

Specific maximum dosage information not available.

Children

Specific maximum dosage information not available.

Infants

3 months and older: Specific maximum dosage information not available.
Younger than 3 months: Safety and efficacy have not been established.

Neonates

Safety and efficacy have not been established.

Crisaborole